Results 31 to 40 of about 91,209 (251)
Repurposing mucosal delivery devices for live attenuated tuberculosis vaccines
Frontiers in Immunology, 2023 Tuberculosis (TB) remains one of the most lethal infectious diseases globally. The only TB vaccine approved by the World Health Organization, Bacille Calmette-Guérin (BCG), protects children against severe and disseminated TB but provides limited ...
Munish Puri +4 more
doaj +1 more source
Protection efficacy of Argentinian isolates of Mycobacterium avium subsp. paratuberculosis with different genotypes and virulence in a murine model [PDF]
, 2018 Paratuberculosis is a chronic disease caused by Mycobacterium avium subsp. paratuberculosis (Map). The disease causes economic losses and, therefore, it is imperative to follow proper control strategies, which should include an effective vaccine. Several
Alvarado Pinedo, María Fiorella +8 more
core +1 more source
A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus [PDF]
, 2014 Bluetongue is one of the major infectious diseases of ruminants and is caused by Bluetongue virus (BTV), an arbovirus existing in nature in at least 26 distinct serotypes. Here, we describe the development of a vaccine platform for BTV.
Brunet, Silvie +6 more
core +2 more sources
Protective immunity against Trypanosoma cruzi [PDF]
, 2009 Upon infection, Trypanosoma cruzi triggers a strong immune response that has both protective and pathological consequences. In this work, several important questions regarding protective immunity are reviewed.
Basombrío, Miguel Ángel Manuel +2 more
core +1 more source
Live-attenuated vaccination in patients with inflammatory bowel disease while continuing or after elective switch to vedolizumab [PDF]
Intestinal ResearchBackground/Aims Vedolizumab (VDZ) is a gut-selective agent with a favorable safety profile. We aimed to assess the feasibility of elective switch from other advanced therapies to VDZ and subsequent live-attenuated vaccination while continuing VDZ in ...
Hisashi Shiga +7 more
doaj +1 more source
Live Attenuated Varicella Vaccine
The Journal of Pediatrics, 1985 Live attenuated varicella vaccine will in all probability soon be licensed in the United States for immunization of healthy children and adults and certain immunocompromised children. This vaccine can be expected to protect susceptibles from varicella (or to modify it) in those subsequently exposed to the wild virus.
openaire +6 more sources
Natural Attenuated Vaccines for Pasteurella multocida
BiologyPasteurella multocida is capable of infecting various animal species, causing hemorrhagic septicemia or infectious pneumonia, and it is widely prevalent and pathogenic worldwide.
Qingyuan Xu +3 more
doaj +1 more source
Vaccines, 2022 Solid dose vaccine formulation and delivery systems offer potential advantages over traditional liquid vaccine formulations. In addition to enhanced thermostability, needle-free delivery of unit solid dose injectable (USDI) vaccines offers safe, rapid ...
Ellie Hayhurst +12 more
doaj +1 more source
Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. [PDF]
, 2015 The polio eradication endgame aims to bring transmission of all polioviruses to a halt. To achieve this aim, it is essential to block viral replication in individuals via induction of a robust mucosal immune response. Although it has long been recognized
Anis E +16 more
core +3 more sources
Live attenuated intranasal influenza vaccine [PDF]
Human Vaccines & Immunotherapeutics, 2012 Annual vaccination is the most effective means of preventing and controlling influenza epidemics, and the traditional trivalent inactivated vaccine (TIV) is by far the most widely used. Unfortunately, it has a number of limitations, the most important of which is its poor immunogenicity in younger children and the elderly, the populations at greatest ...
S. Esposito +5 more
openaire +5 more sources